Abstract |
Tebipenem pivoxil (TBPM-PI), the first oral carbapenem antibiotic both in Japan and abroad, was examined on its convulsive liability. We used ICR male mice and Sprague-Dawley male rats to examine the pro-convulsive effect and anticonvulsive effect of TBPM-PI and its active metabolite, TBPM. (1) When mice were treated with TBPM-PI (30-1000 mg/kg, p.o.) or TBPM (10-300 mg/kg, i.v.), no convulsion was noted at any dose level. When rats were treated with TBPM (300 mg/kg, i.v.), no convulsant effects were noted in electroencephalography or behavioral observation. In intraventricular injection of TBPM in mice, clonic convulsion was observed in 7/10 animals at 100 microg but no effect at 30 microg. On the other hand, the administration of 10/10 microg imipenem/cilastatin (IPM/CS) resulted in clonic convulsion in all animals and tonic convulsion in 3/10 animals, and 4/10 animals died. The administration of 100 microg meropenem did not cause any effects. (2) When mice were co-administered with pentylenetetrazole (45 mg/kg: maximum dose level at which no convulsion is induced) and TBPM-PI (30-300 mg/kg, p.o.) or TBPM (300 mg/kg, i.v.), convulsion enhancing effect was not noted. On the other hand, the co-administration of pentylenetetrazole with IPM/CS (300/300 mg/kg, i.v.) enhanced a convulsive effect of pentylenetetrazole. (3) When mice were treated with TBPM-PI (30-300 mg/kg, p.o.) or TBPM (100 mg/kg, i.v.), inhibitory effect was not noted on convulsions induced by electrostimulation, pentylenetetrazole or strychinine. In conclusion, there were no pro-convulsive effects or anticonvulsive effect in the oral administration of TBPM-PI or intravenous administration of TBPM. Pro-convulsive effect was observed in the intraventricular injection of TBPM as in the case of other carbapenem antibiotics, but such action was weaker than that in IPM/CS administration. Accordingly, the risk of occurrence of convulsion related to TBPM-PI administration was low compared to IPM/CS administration, and TBPM-PI was considered to be less potential to induce convulsions in clinical use.
|
Authors | Yukihiro Yagi, Toru Nawa, Yasushi Kurata, Shigeki Shibasaki, Hisashi Suzuki, Tohru Kurosawa |
Journal | The Japanese journal of antibiotics
(Jpn J Antibiot)
Vol. 62
Issue 3
Pg. 241-52
(Jun 2009)
ISSN: 0368-2781 [Print] Japan |
PMID | 19882983
(Publication Type: Journal Article)
|
Chemical References |
- Carbapenems
- Drug Combinations
- Cilastatin
- Imipenem
- Cilastatin, Imipenem Drug Combination
- tebipenem
- Pentylenetetrazole
|
Topics |
- Administration, Oral
- Animals
- Carbapenems
(administration & dosage, adverse effects)
- Cilastatin
(administration & dosage, adverse effects)
- Cilastatin, Imipenem Drug Combination
- Dose-Response Relationship, Drug
- Drug Combinations
- Drug Synergism
- Imipenem
(administration & dosage, adverse effects)
- Infusions, Intravenous
- Injections, Intraventricular
- Male
- Mice
- Pentylenetetrazole
(adverse effects, pharmacology)
- Rats
- Seizures
(chemically induced)
|